

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1.-49. (Canceled)

50. (Previously Presented) A method of preventing or treating cutaneous inflammation in a subject which comprises administering to the subject an antibody or portion thereof that binds to kit protein in an amount effective to inhibit the kinase enzymatic reaction of kit protein and to inhibit the stem cell factor signaling pathway, thereby preventing or treating cutaneous inflammation in the subject.
51. (Previously Presented) The method of claim 50, wherein the subject is selected from the group consisting of a cow, a horse, a sheep, a pig, a dog, a cat, a rabbit and a primate.
52. (Previously Presented) The method of claim 50, wherein the subject is a human being.
53. (Previously Presented) The method of claim 50, wherein the antibody is a monoclonal antibody.
54. (Previously Presented) The method of claim 53, wherein the monoclonal antibody is a human antibody, a humanized antibody or a chimeric

antibody.

55. (Previously Presented) The method of claim 53, wherein the monoclonal antibody is an anti-c-kit antibody.
56. (Previously Presented) The method of claim 50, wherein the antibody is designated ACK2.
57. (Currently Amended) The method of claim 50, wherein the administering administration is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome-mediated delivery, transmucosal, intestinal, topical, nasal, oral, anal, ocular or otic delivery.